Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion type Assertion NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_head.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion description "[Po-husk, apart from lowering LDL-C, also reduced TG, TG related to certain gene variants, TC, Apo B-100, oxLDL, insulin-resistance and systolic BP in mild-moderate hypercholesterolaemic individuals. Thus, the target patients to receive Po-husk would be those who present a cluster of various CVD risk factors, such as metabolic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_provenance.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion evidence source_evidence_literature NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_provenance.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion SIO_000772 20413122 NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_provenance.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion wasDerivedFrom gad-20130706 NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_provenance.
- NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_assertion wasGeneratedBy ECO_0000203 NP44272.RA6gZgCCgJWimSe1CiO8QOVGyrymXQkPvhZztisCW3yfE130_provenance.